Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1607628

registered interest
date	27/03/2023
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Low Incomes
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what is their latest estimate of the numbers of (1) men, and (2) women, employees who earn less than £12,570 per annum in (a) full-time, and (b) part-time roles.
tabling member printed	Baroness Altmann
uin	HL6837
answer	answer is ministerial correction date of answer 12/04/2023 answer text <p>The information requested falls under the remit of the UK Statistics Authority.</p><p>A response to the Noble Peer’s Parliamentary Question of 27 March is attached in the answer.</p><p> </p><p>The Baroness Altmann CBE</p><p><br>House of Lords<br>London<br>SW1A 0PW</p><p>3 April 2023</p><p>Dear Lady Altmann,</p><p><br>As National Statistician and Chief Executive of the UK Statistics Authority, I am responding to your Parliamentary Question asking what is the latest estimate of the numbers of (1)<br>men, and (2) women, employees who earn less than £12,570 per annum in (a) full-time, and (b) part-time roles (HL6837).</p><p>The Annual Survey of Hours and Earnings (ASHE) [1], carried out in April each year, is the most comprehensive source of earnings information in the United Kingdom. ASHE is based on a 1% sample of employee jobs taken from HM Revenue and Customs' Pay As You Earn (PAYE) records. Table 1 (below) shows the numbers of (1) men, and (2) women, employees who earn less than £12,570 per annum in (a) full-time, and (b) part-time roles for April 20221 (the latest period for which ASHE estimates are available). As with any survey, estimates from ASHE are subject to a margin of uncertainty.</p><p>Yours sincerely,</p><p>Professor Sir Ian Diamond</p><p>Table 1: Estimates of the number of employee jobs with annual earnings below £12,570, UK, 2022 [1,2,3]</p><table><tbody><tr><td><p>Group</p></td><td><p>Number of employee jobs with annual earnings of less than £12,570 (thousands) [2,3]</p></td><td><p>Total number of<br>employee jobs in<br>group (thousands) [2, 3]</p></td></tr><tr><td><p>All employees</p></td><td><p>3,346</p></td><td><p>22,363</p></td></tr><tr><td><p>Male</p></td><td><p>907</p></td><td><p>11,294</p></td></tr><tr><td><p>Female</p></td><td><p>2,439</p></td><td><p>11,069</p></td></tr><tr><td><p>Full-time</p></td><td><p>309</p></td><td><p>16,547</p></td></tr><tr><td><p>Part-time</p></td><td><p>3,037</p></td><td><p>5,817</p></td></tr><tr><td><p>Full-time male</p></td><td><p>134</p></td><td><p>9,856</p></td></tr><tr><td><p>Full-time female</p></td><td><p>175</p></td><td><p>6,691</p></td></tr><tr><td><p>Part-time male</p></td><td><p>773</p></td><td><p>1,439</p></td></tr><tr><td><p>Part-time female</p></td><td><p>2,264</p></td><td><p>4,378</p></td></tr></tbody></table><p>Source: Annual Survey of Hours and Earnings</p><p>[1] Estimates for 2022 are provisional</p><p>[2] Employees on adult rates who have been in the same job for more than a year</p><p>[3] Figures for Number of Jobs are for indicative purposes only and should not be considered an<br>accurate estimate of employee job counts</p> answering member printed Baroness Neville-Rolfe question first answered 12/04/2023 11:41:18 answering member 4284 label Biography information for Baroness Neville-Rolfe attachment 1 file name PQHL6837.pdf title UK Statistics Authority Response
tabling member	4533 label Biography information for Baroness Altmann

1607629

registered interest
date	27/03/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Mobile Phones
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what estimate they have made of the proportion of people in the UK that do not own a smartphone in each of the following age ranges: (1) 18–24, (2) 25–44, (3) 45–64, (4) 65–74, (5) 75–84, and (6) 85 and above.
tabling member printed	Baroness Altmann
uin	HL6838
answer	answer is ministerial correction date of answer 03/04/2023 answer text <p>Data on smartphone use, Wi-Fi and internet access is collected by the Office of Communications and the Office for National Statistics.</p><p>According to Ofcom data, in 2020, the vast majority (85%) of all adults used a smartphone. This rose to more than nine in ten for those aged 16-54. Use was lower for those aged 65+ (55%), who were more likely than average (29%) to use a mobile device that wasn’t a smartphone. The smartphone was the device most likely to be used by people to go online; 85% of internet users used it for this purpose. Older internet users, aged 65+, were less likely to go online via most devices asked about, and in particular, they were less likely to have adopted smart technology, such as a smartphone.</p><p>ONS data indicates that 92% of adults in the UK were recent internet users in 2020, up from 91% in 2019. Almost all adults aged 16 to 44 years in the UK were recent internet users (99%), compared with 54% of adults aged 75 years and over. While there has been little change in internet use for adults aged 16 to 44 years in recent years, the proportion of those aged 75 years and over who are recent internet users nearly doubled since 2013, from 29%, to 54% in 2020. 6.3% of adults in the UK had never used the internet in 2020, down from 7.5% in 2019.</p> answering member printed Viscount Camrose grouped question UIN HL6839 question first answered 03/04/2023 15:29:21 answering member 4939 label Biography information for Viscount Camrose
tabling member	4533 label Biography information for Baroness Altmann

1607630

registered interest
date	27/03/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Internet: Access
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what estimate they have made of the proportion of people in the UK who have no internet or Wi-Fi access in the following age groups: (1) 20–39, (2) 40–59, (3) 60–79, and (4) 80 and above.
tabling member printed	Baroness Altmann
uin	HL6839
answer	answer is ministerial correction date of answer 03/04/2023 answer text <p>Data on smartphone use, Wi-Fi and internet access is collected by the Office of Communications and the Office for National Statistics.</p><p>According to Ofcom data, in 2020, the vast majority (85%) of all adults used a smartphone. This rose to more than nine in ten for those aged 16-54. Use was lower for those aged 65+ (55%), who were more likely than average (29%) to use a mobile device that wasn’t a smartphone. The smartphone was the device most likely to be used by people to go online; 85% of internet users used it for this purpose. Older internet users, aged 65+, were less likely to go online via most devices asked about, and in particular, they were less likely to have adopted smart technology, such as a smartphone.</p><p>ONS data indicates that 92% of adults in the UK were recent internet users in 2020, up from 91% in 2019. Almost all adults aged 16 to 44 years in the UK were recent internet users (99%), compared with 54% of adults aged 75 years and over. While there has been little change in internet use for adults aged 16 to 44 years in recent years, the proportion of those aged 75 years and over who are recent internet users nearly doubled since 2013, from 29%, to 54% in 2020. 6.3% of adults in the UK had never used the internet in 2020, down from 7.5% in 2019.</p> answering member printed Viscount Camrose grouped question UIN HL6838 question first answered 03/04/2023 15:29:21 answering member 4939 label Biography information for Viscount Camrose
tabling member	4533 label Biography information for Baroness Altmann

1599662

registered interest
date	27/02/2023
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Pension Funds: Advisory Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether they intend to adopt the Competition and Market Authority’s recommendation of December 2018 to make investment consultants advising on pension funds subject to regulation by the Financial Conduct Authority; and if so, when.
tabling member printed	Baroness Altmann
uin	HL5877
answer	answer is ministerial correction date of answer 10/03/2023 answer text <p>The principal finding of the Competition and Markets Authority’s (CMA) 2018 Investment Consultants Market Investigation report was that the investment consultancy and fiduciary management market was insufficiently competitive, leading to adverse impacts for their customers. One of the recommendations of that report was that investment consultants should be brought into Financial Conduct Authority’s (FCA) regulation.</p><p> </p><p>In the March 2019 response to the recommendations of the CMA’s final report, HM Treasury committed to consulting on the CMA’s recommendation that the FCA’s regulatory perimeter be extended to cover the activities of investment consultants. A number of other priorities, including the urgent work required to respond to the Covid-19 pandemic, meant that the work to develop this consultation has been delayed.</p><p> </p><p>However, a number of other recommendations made by the CMA to address competition in this market have been taken forward, such as the Department for Work and Pensions’ legislation requiring pension scheme trustees to carry out a competitive tender for fiduciary management services.</p><p> </p><p>HM Treasury works closely with the FCA and has held regular discussions with them on this matter.</p> answering member printed Baroness Penn grouped question UIN HL5878 question first answered 10/03/2023 11:04:58 answering member 4726 label Biography information for Baroness Penn
tabling member	4533 label Biography information for Baroness Altmann

1599663

registered interest
date	27/02/2023
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Pension Funds: Advisory Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what discussions they have had with the Financial Conduct Authority on the regulation of investment consultants for pension fund investors, including the regulation of their net zero and sustainability strategies.
tabling member printed	Baroness Altmann
uin	HL5878
answer	answer is ministerial correction date of answer 10/03/2023 answer text <p>The principal finding of the Competition and Markets Authority’s (CMA) 2018 Investment Consultants Market Investigation report was that the investment consultancy and fiduciary management market was insufficiently competitive, leading to adverse impacts for their customers. One of the recommendations of that report was that investment consultants should be brought into Financial Conduct Authority’s (FCA) regulation.</p><p> </p><p>In the March 2019 response to the recommendations of the CMA’s final report, HM Treasury committed to consulting on the CMA’s recommendation that the FCA’s regulatory perimeter be extended to cover the activities of investment consultants. A number of other priorities, including the urgent work required to respond to the Covid-19 pandemic, meant that the work to develop this consultation has been delayed.</p><p> </p><p>However, a number of other recommendations made by the CMA to address competition in this market have been taken forward, such as the Department for Work and Pensions’ legislation requiring pension scheme trustees to carry out a competitive tender for fiduciary management services.</p><p> </p><p>HM Treasury works closely with the FCA and has held regular discussions with them on this matter.</p> answering member printed Baroness Penn grouped question UIN HL5877 question first answered 10/03/2023 11:04:58 answering member 4726 label Biography information for Baroness Penn
tabling member	4533 label Biography information for Baroness Altmann

1599664

registered interest
date	27/02/2023
answering body	Department for Business and Trade
answering dept id	214
answering dept short name	Business and Trade
answering dept sort name	Business and Trade
hansard heading	Audit
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to bring forward legislation this year to enable the creation of the new Auditing, Reporting and Governance Authority.
tabling member printed	Baroness Altmann
uin	HL5879
answer	answer is ministerial correction date of answer 13/03/2023 answer text <p>The Government will bring forward legislation when Parliamentary time allows.</p> answering member printed Lord Johnson of Lainston question first answered 13/03/2023 13:41:41 answering member 4949 label Biography information for Lord Johnson of Lainston
tabling member	4533 label Biography information for Baroness Altmann

1588978

registered interest
date	23/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunosuppression: Coronavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that immunocompromised people for whom vaccination is not suitable are protected against COVID-19.
tabling member printed	Baroness Altmann
uin	HL5824
answer	answer is ministerial correction date of answer 01/03/2023 answer text <p>Those who are at higher risk of serious outcomes from COVID-19, including the immunosuppressed and/or immunocompromised, remain a priority for the Government and as such are offered enhanced protections and interventions such as treatments, vaccines, and public health advice. The Government recently updated the online-only <em>COVID-19: guidance for people whose immune system means they are at higher risk</em> on 30 January 2023.</p><p> </p><p>In rare cases where people may have a medical contraindication to currently available COVID-19 vaccines, individuals are able to access services such as a referral to an allergist or other appropriate specialist, to consider administration of the implicated mRNA vaccine under medical supervision in a suitable environment. When mRNA vaccines are not considered clinically suitable, the Novavax COVID-19 vaccine Nuvaxovid, a protein subunit vaccine, may be used as an alternative for people who are contraindicated against and cannot have any alternative clinically suitable United Kingdom-approved COVID-19 vaccine. The Government continues to be guided by the independent Joint Committee on Vaccination and Immunisation on the COVID-19 vaccination programme.</p><p> </p><p>Immunosuppressed individuals are also a priority cohort for research into therapeutic and prophylaxis treatments such as monoclonal antibody therapies, novel antivirals, and repurposed compounds.</p><p> </p><p>The Government has made available a range of new treatment options within the community for National Health Service patients at greater risk from COVID-19. These treatments are licensed for use in non-hospitalised patients to reduce the risk of hospitalisation and death.</p><p> </p><p>There are two ways for clinically eligible patients to access these new treatments. Those in the highest risk group from COVID-19 with a positive COVID-19 test result can access the treatments directly, following advice from a clinician at a COVID Medicines Delivery Unit. In addition, oral antiviral treatments are available through the national study, PANORAMIC, run by the University of Oxford. This study is open to clinically eligible individuals living anywhere in the UK. Further details about eligibility can be found on the PANORAMIC website in an online-only format.</p> answering member printed Lord Markham question first answered 01/03/2023 11:59:49 answering member 4948 label Biography information for Lord Markham
tabling member	4533 label Biography information for Baroness Altmann

1588979

registered interest
date	23/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Immunosuppression
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the finding from the National Institute for Health and Care Excellence (NICE) that "Evusheld is not recommended for vulnerable adults who are at high risk of severe COVID-19 because there is not enough evidence of its effectiveness against current variants and those likely to be circulating in the next 6 months", what consideration they have given to using human-derived convalescent plasma for immune compromised individuals; and what trials they have undertaken, if any, to test its effectiveness.
tabling member printed	Baroness Altmann
uin	HL5825
answer	answer is ministerial correction date of answer 02/03/2023 answer text <p>For treatment of patients with COVID-19, the REMAP-CAP and RECOVERY trials both found convalescent plasma did not provide any benefit to the overall patient group. However, detailed analysis within subgroups of the REMAP-CAP data found there was a likelihood that people who are immunosuppressed may benefit from convalescent plasma with very high antibody levels - unfortunately there was insufficient data for a definite result. Consequently, REMAP-CAP has now decided to reopen the convalescent plasma arm to collect more data.</p><p> </p><p>Further research is needed to determine the benefit of using human-derived convalescent plasma, or products derived from it, for immunocompromised individuals before this could be approved and available to patients. The Department commissions research through the National Institute for Health and Care Research (NIHR). NIHR welcomes funding applications for research into any aspect of human health, including immunoglobulins and convalescent plasma.</p> answering member printed Lord Markham grouped question UIN HL5826 question first answered 02/03/2023 13:13:10 answering member 4948 label Biography information for Lord Markham
tabling member	4533 label Biography information for Baroness Altmann

1588980

registered interest
date	23/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Immunosuppression
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to (1) the Written Answer by Lord Markham on 20 February (HL5171), and (2) the conclusion from the National Institute for Health and Care Excellence (NICE) that "Evusheld is not recommended for vulnerable adults who are at high risk of severe COVID-19 because there is not enough evidence of its effectiveness against current variants and those likely to be circulating in the next 6 months", what steps they will now take to ensure that immunocompromised individuals have access to passive immunisation via relevant human-derived antibody products from convalescent plasma, instead of through monoclonal antibody treatments.
tabling member printed	Baroness Altmann
uin	HL5826
answer	answer is ministerial correction date of answer 02/03/2023 answer text <p>For treatment of patients with COVID-19, the REMAP-CAP and RECOVERY trials both found convalescent plasma did not provide any benefit to the overall patient group. However, detailed analysis within subgroups of the REMAP-CAP data found there was a likelihood that people who are immunosuppressed may benefit from convalescent plasma with very high antibody levels - unfortunately there was insufficient data for a definite result. Consequently, REMAP-CAP has now decided to reopen the convalescent plasma arm to collect more data.</p><p> </p><p>Further research is needed to determine the benefit of using human-derived convalescent plasma, or products derived from it, for immunocompromised individuals before this could be approved and available to patients. The Department commissions research through the National Institute for Health and Care Research (NIHR). NIHR welcomes funding applications for research into any aspect of human health, including immunoglobulins and convalescent plasma.</p> answering member printed Lord Markham grouped question UIN HL5825 question first answered 02/03/2023 13:13:10 answering member 4948 label Biography information for Lord Markham
tabling member	4533 label Biography information for Baroness Altmann

1581692

registered interest
date	30/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Immunosuppression
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the decision by regulatory authorities in the United States of America to disallow further use of the Evusheld monoclonal antibody product; and what steps they will take to ensure appropriate prophylaxis and treatment against COVID-19 for vulnerable immunodeficient and immunocompromised patients.
tabling member printed	Baroness Altmann
uin	HL5171
answer	answer is ministerial correction date of answer 20/02/2023 answer text <p>The Antivirals and Therapeutics Taskforce engages with other nations to share learning on the use, deployment and evaluation of therapeutics and antivirals. Evusheld (tixagevimab and cilgavimab) has a conditional marketing authorisation in the United Kingdom for the pre-exposure prophylaxis of COVID-19 and has been referred to the National Institute for Health and Care Excellence (NICE) to make recommendations for the National Health Service on whether it should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness.</p><p> </p><p>The final outcome of NICE’s evaluation on the use of Evusheld as a pre-exposure prophylactic treatment against COVID-19 is expected in April 2023.</p> answering member printed Lord Markham question first answered 20/02/2023 15:38:18 answering member 4948 label Biography information for Lord Markham
tabling member	4533 label Biography information for Baroness Altmann